Form 4: Ultragenyx Director Michael Narachi Acquires Stock Options and Restricted Stock Units

Director Michael Narachi acquired stock options and restricted stock units in Ultragenyx Pharmaceutical Inc. on June 18, 2024.

Summary

• On June 18, 2024, Michael Narachi, a director of Ultragenyx Pharmaceutical Inc., acquired 5,345 shares of common stock through restricted stock units (RSUs) and was granted options to purchase 9,900 shares of common stock.
• The RSUs were awarded under the company's 2023 Incentive Plan and will vest on the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.
• The stock options have an exercise price of $37.42 and will vest on the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.
• Following these transactions, Narachi directly owns 26,950 shares of Ultragenyx common stock and holds options for 9,900 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs to a director is a common practice and generally viewed as a positive sign, aligning the director's interests with those of the shareholders. There are no explicitly negative aspects in the filing.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule tied to the Annual Meeting of Stockholders or a specific date (June 18, 2025) encourages continued service and commitment from the director.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs to a director as a positive sign, aligning their interests with those of the company's leadership.

Key Dates